74
Growth Score
pts
Heat Score
73 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
548099
Adjuvant Genomics, Inc. develops a genomic assay that stratifies Stage 1–2 NSCLC patients by recurrence risk from adjuvant chemotherapy.
- Robert Jacoby: Chief Business Officer
About the Company
Adjuvant Genomics, Inc. develops a genomic assay to guide adjuvant treatment decisions for early-stage non-small cell lung cancer. The assay uses tumor-derived molecular signatures to identify patients at high risk of recurrence after curative resection. It also predicts the likelihood that an individual patient will benefit from adjuvant
chemotherapy. This information helps clinicians select between chemotherapy and alternative adjuvant options and avoid unnecessary toxicity. The company focuses on integrating clinical validation data to support personalized NSCLC care.
